Ignite Creation Date:
2024-05-06 @ 3:04 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04511715
Status:
UNKNOWN
Last Update Posted:
2020-08-13
First Post:
2020-08-11
Brief Title:
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
Sponsor:
Shahid Beheshti University of Medical Sciences
Organization:
Shahid Beheshti University of Medical Sciences
Study Overview
Official Title:
Efficacy and Safety of Intravitreal Bevacizumab for the Improvement of Severe Non-proliferative Diabetic Retinopathy Without DME a Randomized Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2020-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this randomized clinical trial 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups Intravitreal Bevacizumab group 50 eyes that receive 6 bimonthly intravitreal bevacizumab and control group 50 eyes that undergo regular follow-up for Diabetic Retinopathy Diabetic macular edema DME will be treated independently in all groups by intravitreal bevacizumab Primary outcome will be the percentage of patients with progression of 2 or more stages through international diabetic retinopathy staging The secondary measures will be changes in best corrected visual acuity BCVA and central macular thickness CMT and number of examinations and injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None